BACKGROUND: The cell surface glycoprotein E-cadherin (CDH1) is a key regulator of adhesive properties in epithelial cells. Germline mutations in CDH1 are well established as the defects underlying hereditary diffuse gastric cancer (HDGC) syndrome, and an increased risk of lobular breast cancer (LBC) has been described in HDGC kindreds. However, germline CDH1 mutations have not been described in patients with LBC in non-HDGC families. This study aimed to investigate the frequency of germline CDH1 mutations in patients with LBC with early onset disease or family histories of breast cancer without DGC. METHODS: Germline DNA was analysed in 23 women with invasive lobular or mixed ductal and lobular breast cancers who had at least one close relative with breast cancer or had themselves been diagnosed before the age of 45 years, had tested negative for a germline BRCA1 or BRCA2 mutation, and reported no personal or family history of diffuse gastric cancer. The full coding sequence of CDH1 including splice junctions was amplified using PCR and screened for mutations using DHPLC and sequencing. RESULTS: A novel germline CDH1 truncating mutation in the extracellular portion of the protein (517insA) was identified in one woman who had LBC at the age of 42 years and a first degree relative with invasive LBC. CONCLUSIONS: Germline CDH1 mutations can be associated with invasive LBC in the absence of diffuse gastric cancer. The finding, if confirmed, may have implications for management of individuals at risk for this breast cancer subtype. Clarification of the cancer risks in the syndrome is essential.
BACKGROUND: The cell surface glycoprotein E-cadherin (CDH1) is a key regulator of adhesive properties in epithelial cells. Germline mutations in CDH1 are well established as the defects underlying hereditary diffuse gastric cancer (HDGC) syndrome, and an increased risk of lobular breast cancer (LBC) has been described in HDGC kindreds. However, germline CDH1 mutations have not been described in patients with LBC in non-HDGC families. This study aimed to investigate the frequency of germline CDH1 mutations in patients with LBC with early onset disease or family histories of breast cancer without DGC. METHODS: Germline DNA was analysed in 23 women with invasive lobular or mixed ductal and lobular breast cancers who had at least one close relative with breast cancer or had themselves been diagnosed before the age of 45 years, had tested negative for a germline BRCA1 or BRCA2 mutation, and reported no personal or family history of diffuse gastric cancer. The full coding sequence of CDH1 including splice junctions was amplified using PCR and screened for mutations using DHPLC and sequencing. RESULTS: A novel germline CDH1 truncating mutation in the extracellular portion of the protein (517insA) was identified in one woman who had LBC at the age of 42 years and a first degree relative with invasive LBC. CONCLUSIONS: Germline CDH1 mutations can be associated with invasive LBC in the absence of diffuse gastric cancer. The finding, if confirmed, may have implications for management of individuals at risk for this breast cancer subtype. Clarification of the cancer risks in the syndrome is essential.
Authors: C Caldas; F Carneiro; H T Lynch; J Yokota; G L Wiesner; S M Powell; F R Lewis; D G Huntsman; P D Pharoah; J A Jankowski; P MacLeod; H Vogelsang; G Keller; K G Park; F M Richards; E R Maher; S A Gayther; C Oliveira; N Grehan; D Wight; R Seruca; F Roviello; B A Ponder; C E Jackson Journal: J Med Genet Date: 1999-12 Impact factor: 6.318
Authors: G Berx; A M Cleton-Jansen; K Strumane; W J de Leeuw; F Nollet; F van Roy; C Cornelisse Journal: Oncogene Date: 1996-11-07 Impact factor: 9.867
Authors: G Keller; H Vogelsang; I Becker; J Hutter; K Ott; S Candidus; T Grundei; K F Becker; J Mueller; J R Siewert; H Höfler Journal: Am J Pathol Date: 1999-08 Impact factor: 4.307
Authors: P Guilford; J Hopkins; J Harraway; M McLeod; N McLeod; P Harawira; H Taite; R Scoular; A Miller; A E Reeve Journal: Nature Date: 1998-03-26 Impact factor: 49.962
Authors: A R Brooks-Wilson; P Kaurah; G Suriano; S Leach; J Senz; N Grehan; Y S N Butterfield; J Jeyes; J Schinas; J Bacani; M Kelsey; P Ferreira; B MacGillivray; P MacLeod; M Micek; J Ford; W Foulkes; K Australie; C Greenberg; M LaPointe; C Gilpin; S Nikkel; D Gilchrist; R Hughes; C E Jackson; K G Monaghan; M J Oliveira; R Seruca; S Gallinger; C Caldas; D Huntsman Journal: J Med Genet Date: 2004-07 Impact factor: 6.318
Authors: G Berx; A M Cleton-Jansen; F Nollet; W J de Leeuw; M van de Vijver; C Cornelisse; F van Roy Journal: EMBO J Date: 1995-12-15 Impact factor: 11.598
Authors: Kathryn S P Higginbotham; Joan P Breyer; Kevin M Bradley; Peggy A Schuyler; W Dale Plummer; Marcia E Freudenthal; Amy Trentham-Dietz; Polly A Newcomb; Melinda E Sanders; David L Page; Fritz F Parl; Kathleen M Egan; William D Dupont; Jeffrey R Smith Journal: Cancer Res Date: 2011-05-24 Impact factor: 12.701
Authors: Anna Jakubowska; Małgorzata Lawniczak; Beata Wojnarska; Cezary Cybulski; Tomasz Huzarski; Tomasz Byrski; Aleksandra Tołoczko-Grabarek; Katarzyna Jaworska; Katarzyna Durda; Teresa Starzyńska; Jan Lubiński Journal: Fam Cancer Date: 2010-12 Impact factor: 2.375
Authors: Donghui Zou; Han-Seung Yoon; Ahmad Anjomshoaa; David Perez; Ryuji Fukuzawa; Parry Guilford; Bostjan Humar Journal: Breast Cancer Res Date: 2009-07-07 Impact factor: 6.466